{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-168521","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.570953+00:00","generated_at":"2026-05-15T04:57:38.641553+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tenax Therapeutics appoints Thomas R. Staab, II as CFO effective May 11, 2026","bullets":["Staab, a 25-year healthcare finance veteran, most recently CFO of LENSAR (LNSR) until May 2026.","Base salary of $428,000 with 45% target bonus; inducement equity of 10,000 RSUs and 450,000 option shares.","Interim CFO Thomas McGauley resigns May 10, 2026 but will stay through filing of Q1 10-Q and provide consulting transition.","Staab's RSUs vest 25% after 10 days, remainder quarterly; options vest 25% after 1 year then monthly over 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-168521","json":"https://secwatch.observer/filing/0001193125-26-168521.json","markdown":"https://secwatch.observer/filing/0001193125-26-168521.md","text":"https://secwatch.observer/filing/0001193125-26-168521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000119312526168521/0001193125-26-168521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000119312526168521/d81080d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:57:38.641553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}